Could Celldex Be a Millionaire-Maker Stock?
Making a move before anyone else can see the value in a company's therapy candidate isn't an exact science, and investors need at least a little bit of luck along the way if they're going to get rich. Celldex Therapeutics (NASDAQ: CLDX) is developing immunotherapeutic antibodies that could one day be used to treat seemingly intractable diseases like metastatic pancreatic cancer and urticaria. The company's efforts are just getting started, and it must complete a marathon of clinical trials in the years ahead before it can hope to report any earnings.
